Cue Biopharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CUE research report →
Companywww.cuebiopharma.com
Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.
- CEO
- Lucinda Warren
- IPO
- 2018
- Employees
- 41
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $53.69M
- P/E
- -5.03
- P/S
- 1.64
- P/B
- 4.55
- EV/EBITDA
- -2.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.52%
- Op Margin
- -59.80%
- Net Margin
- -59.65%
- ROE
- -98.30%
- ROIC
- -78.15%
Growth & Income
- Revenue
- $27.47M · 195.75%
- Net Income
- $-26,602,000 · 34.60%
- EPS
- $-8.40 · 61.11%
- Op Income
- $-26,521,000
- FCF YoY
- 39.93%
Performance & Tape
- 52W High
- $41.42
- 52W Low
- $4.98
- 50D MA
- $16.11
- 200D MA
- $16.87
- Beta
- 2.39
- Avg Volume
- 763.46K
Get TickerSpark's AI analysis on CUE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 30, 26 | Lin Shao-Lee | other | 0 |
| May 3, 26 | Lin Shao-Lee | other | 655,074 |
| May 3, 26 | Lin Shao-Lee | other | 327,537 |
| Apr 9, 26 | Sandercock Colin | other | 200,000 |
| Apr 9, 26 | Warren Lucinda | other | 250,000 |
| Apr 9, 26 | Baker Daniel G. | other | 100,000 |
| Jan 2, 26 | Kiener Peter A | other | 24,400 |
| Jan 2, 26 | Broadfoot Jill Marie | other | 24,400 |
| Jan 2, 26 | Garzone Pamela | other | 24,400 |
| Jan 2, 26 | Morich Frank | other | 24,400 |
Our CUE Coverage
We haven't published any research on CUE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CUE Report →